Takeda logo



May 17, 2019

当社は、2019年5月31日から6月4日にかけて米国 シカゴで開催される第55回米国臨床腫瘍学会(ASCO)年次集会において、1つのオーラルプレゼンテーションを含む8件の発表を行い、2019年6月13日から16日にかけてオランダ アムステルダムで開催される第24回欧州血液学会(EHA)学術集会において1つのオーラルプレゼンテーションを含む11件の発表を行いますのでお知らせします。



  • Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions (抄録番号9007、オーラルプレゼンテーション、6月3日8:00 – 11:00、Hall B1)
  • Brigatinib (BRG) Versus Crizotinib (CRZ) in Asian Versus Non-Asian Patients (pts) in the Phase 3 ALTA-1L Trial (抄録番号9026、6月2日8:00 – 11:00、Hall A)
  • Phase 2 Study of Brigatinib in Patients (pts) with Anaplastic Lymphoma Kinase (ALK)−Positive, Advanced Non–Small Cell Lung Cancer (NSCLC) that Progressed on Alectinib or Ceritinib (抄録番号TPS9115、6月2日8:00 – 11:00、Hall A)
  • Health-Related Quality of Life (HRQoL) Results from ALTA-1L: Phase 3 Study of Brigatinib vs Crizotinib as First-Line (1L) ALK Therapy in Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC) (抄録番号9084、6月2日8:00 – 11:00、Hall A)
  • Phase 3 PhALLCON Study: Ponatinib (PON) vs Imatinib (IM) With Reduced-Intensity Chemotherapy (CT) in Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) ALL (抄録番号TPS7061、6月3日8:00 – 11:00、Hall A)
  • Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma: Three-Year Update of the ECHELON-1 Study (抄録番号7532、6月3日8:00 – 11:00、Hall A)
  • Response to Brentuximab Vedotin by CD30 Expression: Results from Five Trials in PTCL, CTCL, and B-Cell Lymphomas (抄録番号7543、6月3日8:00 – 11:00、Hall A)
  • Response to A+CHP by CD30 Expression in the ECHELON-2 Trial (抄録番号7538、6月3日8:00 – 11:00、Hall A)


  • Deepening Responses Seen with Ixazomib Maintenance Post-Autologous Stem Cell Transplantation (ASCT) are Associated with Prolonged Progression-Free Survival – Analysis from the TOURMALINE-MM3 Study (抄録番号PS1382、6月15日17:30 – 19:00、ポスターエリア)
  • Health-related Quality of Life (HRQoL) Outcomes of Oral Ixazomib Maintenance Therapy Post Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma (NDMM) from TOURMALINE-MM3 (抄録番号PF626、6月14日17:30 – 19:00、ポスターエリア)
  • Evolving Treatment Patterns in Multiple Myeloma (MM) Differ by Age and Region: Analysis from INSIGHT-MM, A Global, Prospective, Observational Study (抄録番号PF601、6月14日17:30 – 19:00、ポスターエリア)
  • Long-Term Proteasome Inhibition (LTPI) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): US MM-6, A Real-World (RW) Study Transitioning from Bortezomib (Btz) to Ixazomib (Ixa) (抄録番号PF729、6月14日17:30 – 19:00、ポスターエリア)
  • Comparative Effectiveness of Triplets Containing Bortezomib (B), Carfilzomib (C), Daratumumab (D), or Ixazomib (I) in Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the US(抄録番号PS1419、6月15日17:30 – 19:00、ポスターエリア)
  • Characteristics and Treatment Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Non-Stem Cell Transplant (nSCT) Patients in the UK, Germany, and France (抄録番号PS1411、6月15日17:30 – 19:00、ポスターエリア)
  • Evolving Treatment Patterns in Non-Stem Cell Transplant (nSCT) Newly Diagnosed Multiple Myeloma (NDMM): Results from a Real-World Chart Review in France, Germany, and the UK (抄録番号PS1416、6月15日17:30 – 19:00、ポスターエリア)
  • Impact of Patients Characteristics on Health-Related Quality of Life in Patients with Relapsed or Refractory Multiple Myeloma: Results From The CharisMMa Study (抄録番号PF615、6月14日17:30 – 19:00、ポスターエリア)
    • Brentuximab Vedotin With Chemotherapy for Stage 3 and 4 Classical Hodgkin Lymphoma: ECHELON-1 3-Year Results (抄録番号S820、オーラルプレゼンテーション、6月15日12:00 – 12:15、Hall 5)
  • The ECHELON-2 Trial: Results of a Randomized, Double-Blind Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (抄録番号PS1070、6月15日17:30 – 19:00、ポスターエリア)
  • Contemporary Treatment Patterns and Response in Relapse/Refractory Cutaneous T-Cell Lymphoma (CTCL) in Clinical Practice in France, Germany, Italy, Spain and the United Kingdom (抄録番号PS1256、6月15日17:30 – 19:00、ポスターエリア)